E. BİLGİN Et Al. , "Comparison of cardiovascular, cancer and herpes zoster risk of tofacitinib versus etanercept: single-centre observational study," RHEUMATOLOGY , vol.61, no.9, 2022
BİLGİN, E. Et Al. 2022. Comparison of cardiovascular, cancer and herpes zoster risk of tofacitinib versus etanercept: single-centre observational study. RHEUMATOLOGY , vol.61, no.9 .
BİLGİN, E., SARIYILDIZ, E., ÜNALDI, E., KALYONCU, U., KİRAZ, S., & Ertenli, I., (2022). Comparison of cardiovascular, cancer and herpes zoster risk of tofacitinib versus etanercept: single-centre observational study. RHEUMATOLOGY , vol.61, no.9.
BİLGİN, EMRE Et Al. "Comparison of cardiovascular, cancer and herpes zoster risk of tofacitinib versus etanercept: single-centre observational study," RHEUMATOLOGY , vol.61, no.9, 2022
BİLGİN, EMRE Et Al. "Comparison of cardiovascular, cancer and herpes zoster risk of tofacitinib versus etanercept: single-centre observational study." RHEUMATOLOGY , vol.61, no.9, 2022
BİLGİN, E. Et Al. (2022) . "Comparison of cardiovascular, cancer and herpes zoster risk of tofacitinib versus etanercept: single-centre observational study." RHEUMATOLOGY , vol.61, no.9.
@article{article, author={EMRE BİLGİN Et Al. }, title={Comparison of cardiovascular, cancer and herpes zoster risk of tofacitinib versus etanercept: single-centre observational study}, journal={RHEUMATOLOGY}, year=2022}